Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Danazol
Drug ID BADD_D00576
Description A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Indications and Usage For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
Marketing Status approved
ATC Code G03XA01
DrugBank ID DB01406
KEGG ID D00289
MeSH ID D003613
PubChem ID 28417
TTD Drug ID D09IPV
NDC Product Code 38779-0174; 0555-0635; 0555-0633; 62135-477; 0527-1369; 71205-862; 0527-1392; 53104-7501; 71052-662; 62135-476; 62135-475; 0527-1368; 49452-2436; 71205-861; 49076-5201; 0555-0634
UNII N29QWW3BUO
Synonyms Danazol | Danazant | Panacrine | Danocrine | Ladogal | Cyclomen | Danatrol | Danol | Danoval | Norciden | Azol | Danazol-Ratiopharm | Danazol Ratiopharm
Chemical Information
Molecular Formula C22H27NO2
CAS Registry Number 17230-88-5
SMILES CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis23.03.04.002--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.003541%
Drug ineffective08.06.01.0060.005902%Not Available
Dyspepsia07.01.02.001--
Dysphonia22.12.03.006; 19.19.03.002; 17.02.08.004--
Enlarged clitoris21.08.02.001; 05.05.01.004--Not Available
Enzyme abnormality14.11.01.015--Not Available
Eosinophilia01.02.04.001--
Epilepsy17.12.03.002--Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Fatigue08.01.01.0020.003541%
Feeling abnormal08.01.09.0140.003541%Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.003541%Not Available
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Glucose tolerance test abnormal13.02.02.011--Not Available
Guillain-Barre syndrome10.04.10.005; 17.09.01.001; 11.07.01.001--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Headache17.14.01.0010.005902%
Hepatic adenoma16.06.01.002; 09.04.01.002--Not Available
Hepatic failure09.01.03.0020.002361%
Hepatic function abnormal09.01.02.001--Not Available
Hepatic neoplasm16.07.03.001; 09.04.03.001--Not Available
Hepatitis09.01.07.004--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene